Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc. (NASDAQ:RVMD), filed a Form 4 on September 22, 2026, reporting the sale of 1,764 shares of common stock on September 18, 2026.
Key Highlights
- Reporting person: Anthony Mancini, Chief Global Commercialization Officer of Revolution Medicines, Inc.
- Transaction: 1,764 shares of common stock disposed of (transaction code S) on September 18, 2026.
- Sale price: $196.94 per share.
- Remaining ownership: 40,352 shares of common stock held directly following the transaction.
- 10b5-1 plan: The sale was made pursuant to a Rule 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
Mancini Share Sale Details Under Pre-Arranged Trading Plan
According to the filing, Anthony Mancini, identified as Chief Global Commercialization Officer of Revolution Medicines, Inc., sold 1,764 shares of the company's common stock on September 18, 2026, at a price of $196.94 per share. The transaction was recorded as a direct disposition and carries transaction code S in the filing.
The filing notes that the transaction was made pursuant to a 10b5-1 trading plan that Mancini adopted on June 11, 2026. The Form 4 box indicating that the transaction was "made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)" is checked. Following the reported sale, the filing discloses that Mancini directly held 40,352 shares of Revolution Medicines common stock. No derivative securities transactions were reported in Table II of the filing.
The Form 4 was signed by Jack Anders as attorney-in-fact for Anthony Mancini and filed with the SEC on September 22, 2026. No amendment date was listed, indicating this is an original filing. The issuer is identified in the filing as Revolution Medicines, Inc., with the ticker symbol RVMD, listed on NASDAQ.
What Was Disclosed
The filing disclosed a single open-market sale of 1,764 shares of Revolution Medicines common stock by Chief Global Commercialization Officer Anthony Mancini on September 18, 2026, at $196.94 per share, executed under a pre-established 10b5-1 trading plan adopted June 11, 2026.



Please wait processing your request...